POSITIVELY PRECISE.
We’re developing targeted therapies to lower LDL-cholesterol for patients not adequately treated with current lipid-modifying therapies.
Learn More
Pipeline
Esperion is a pharmaceutical company focused on developing and commercializing non-statin, once-daily, oral, LDL-C–lowering therapies for the treatment of patients with hypercholesterolemia.
learn moreRECENT PRESS RELEASES
- Esperion to Present at the Needham & Company 18th Annual Healthcare Conference
- Esperion Announces Publication in The Journal of the American Heart Association of Bempedoic Acid Study 3 Results
- Esperion Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at the American College of Cardiology 2019 Scientific Sessions